Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks